Clinical Trials Logo

B-Cell Lymphomas clinical trials

View clinical trials related to B-Cell Lymphomas.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT02650414 Recruiting - B Cell Lymphomas Clinical Trials

CD22 Redirected Autologous T Cells for ALL

Start date: January 13, 2016
Phase: Phase 1
Study type: Interventional

This is a single center, single arm, open-label pilot study to determine the feasibility and safety of a single dose administered as spilt fractions of autologous T cells expressing CD22 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ/4-1BB) co-stimulatory domains (referred to as "CART22" cells) in pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

NCT ID: NCT02247609 Recruiting - B-cell Lymphomas Clinical Trials

Evaluation of 4th Generation Safety-designed CAR T Cells Targeting High-risk and Refractory B Cell Lymphomas

4SCAR19273
Start date: January 2014
Phase: Phase 1/Phase 2
Study type: Interventional

Currently, a majority of B cell lymphomas cannot be cured by standard chemo-radiotherapy. Most B cell lymphomas express cluster of differentiation antigen 19 (CD19), which represents a very attractive target for chimeric antigen receptor (CAR)-based immune cell therapy. This study will evaluate a novel 4th generation CD19 CAR engineered with a self-withdrawal mechanism (19273-4SCAR) for both efficacy and safety in lymphoma patients.

NCT ID: NCT00801216 Recruiting - B-Cell Lymphomas Clinical Trials

High-Dose Sequential Chemoimmunotherapy for B-Cell Lymphomas With Central Nervous System Involvement

SCNSL1
Start date: January 2007
Phase: Phase 2
Study type: Interventional

This prospective trial will assess the activity and feasibility of a new high-dose methotrexate-based high-dose sequential chemotherapy combination in patients with B-cell lymphomas and CNS involvement at diagnosis or relapse. Selected drugs, with a well-documented anti-lymphoma activity, will be administered at high doses to increase blood-brain barrier penetration and CNS bioavailability as well as to reduce potential cross-resistance.